

ASAHI INTECC CO., LTD.

Company Profile

December, 2025

(Securities code: 7747 Prime of Tokyo Stock Exchange and Premier of Nagoya Stock Exchange)

Company Profile

ASAHI INTECC CO., LTD.
3-100 Akatsuki-cho, Seto-shi, Aichi, Japan
Kenji Miyata, President & CEO
July 8, 1976 (Currently, the 50th term)
Development, manufacturing and sale of medical devices Development, manufacturing and sale of ultra-fine stainless steel wire ropes, terminal processed products, etc.
120,025 Mil.Yen (FYE June 2025)
30,079 Mil. Yen (FYE June 2025)
18,860 Mil. Yen (FYE June 2025)
1,207 (Asahi Intecc only) 9,570 (Total)
20 Consolidated subsidiaries, 5 Non-consolidated subsidiaries
Japan, Thailand, US
Thailand, Vietnam, Philippines, China *
Japan, US, Netherlands, France, Germany, Italy, Russia, China, South Korea, Taiwan, Hong Kong, Singapore, Thailand, India, UAE, Brazil, Saudi Arabia
Tokyo Stock Exchange Prime Market, Nagoya Stock Exchange Premier Market (Securities code 7747) <as 2025="" end="" of="" sep.="" the=""></as>

^{*} Regarding the China factory, operation is scheduled to start around December 2030.



Global Network — R&D/Production

(Coexistence of Japan & Overseas)







THAILAND: ASAHI INTECC THAILAND CO., LTD.



China: **Asahi Inda Medical Equipment** (Nanning) Co., Ltd.

> *****Scheduled to begin operations around December 2030.

[JAPAN] R&D/Prototype

AND R&D CENTER

(Product R&D



VIETNAM: ASAHI INTECC HANOI CO., LTD. **Production 3 Bases** 1 Base in Preparation


> **PHILIPPINES:** TOYOFLEX CEBU CORPORATION

[OVERSEAS] **Production bases**

Japan conducts R&D and prototyping; mass production takes place in overseas factories.



Sales Bases



R&D Bases

R&D of high-precision processing techniques

Tohoku R&D Center



Product Improvement Development Production Technology Development

ASAHI INTECC THAILAND CO., LTD.



Material Development

Osaka R&D Center



Product Development and Prototype manufacturing

Global Headquarters and R&D Center





State-of-the-art R&D

R&D-type company in the US ASAHI Medical Technologies, Inc. (Former name : Retro Vascular, Inc.)

R&D for the **US**

ASAHI INTECC USA, INC.



CDMO

Rev. 1 Engineering, Inc.



Advanced technology development

Tokyo R&D Center



Resin Development

Shizuoka R&D Center



Business Fields and Divisions

■ FYE June 2025
Revenue 120,025Mill. Yen
Operating income 30,079Mill. Yen



Industrial Field (approx. 4%)

Device Division

(Medical Components / Industrial Components)



Expanding from the Industrial Components Field to the Medical Device Field

Leveraging the ultra-fine stainless steel wire rope technology cultivated in the industrial (Unit: Mil.Yen) 140,000 components field, we have entered the medical device field. In particular, the overseas market for the medical division has grown significantly. Medical Overseas 120,000 Medical Domestic Device 100.000 **Establi Entered** Listed the **Expanding** shed 80.000 medical in July overseas in device markets 2004 business ultra-fine stainles **1976** 60.000 PCI guide wire steel wire in 1994 40,000 20,000 Medical device sales (Promotion in Japan and Overseas) Medical device sales Medical device sales (Direct sales in Japan) (Direct sales in Japan) Medical device Medical device manufacture Medical device manufacture manufacture Industrial equipment Industrial equipment Industrial equipment manufacture Industrial equipment manufacture manufacture manufacture Industrial Medical Device Global Medical Device Company Component Finished Medical Device Manufacturer Company Manufacturer



Business Overview and Main Product Groups


Starting from the manufacturing of wire ropes for industrial machine, expanding business into the medical device field (Access devices)

Device Division 10%

Medical Division 90%

Industrial Field 4%

Medical Field 96%




Founded

Entered medical device business in 1994



Main Products of Medical Device




Our main product at 48.2% (FYE June 2025) of Revenue



PCI (Percutaneous Coronary Intervention)-1

- Therapy for coronary artery disorder (angina, myocardial infarction)
- Recover the blood flow after dilatation of stenosed lesion
- Treatment through femoral or radial artery without laparotomy and thoracotomy to minimize the mental and physical burden on patients.




PCI (Percutaneous Coronary Intervention)-2

For PCI treatment to be successful, the PCI guidewire must reach the affected area


1 PCI GW Advancement

Small size tube called PCI Guiding Catheter inserted in blood vessel. Advance PCI GW inside of this tube.




3 PCI Balloon Catheter dilatation

Dilate Balloon, then enlarge the blood vessel.




② PCI Balloon Catheter Tracking


Along with PCI GW, PCI Balloon Catheter trucked over PCI GW to the point of the narrowed portion of vessel.



4 PCI Balloon Catheter pulled out

After Narrow portion enlarged then blood flow to recover.






PCI (Percutaneous Coronary Intervention)-3

Comparatively easy lesions




Lesions with high difficulty



Market Trend:

Market Share of Our Main Product PCI GW [FYE June 2025]



Continue to strive to expand market share in all regions



Technological Advantages:

4 Core Technologies

High transmissibility of rotation(Torquability)



Tip flexibility(Safe operation)

Doctors manipulate the wire and try to transfer the feeling of finger tip to the distal end of wire.

Source of competitiveness: 4 core technologies

Integrated production system handling materials down to the finished products

Control of hardness and diameter



Wire drawing technology

Wire forming technology

Micron-level molding



Rotation following capacity



Torque technology


Resin coating technology

Ultra-thin film coating



Our Company's Flagship CTO Treatment:

Implementation of PCI Treatment in CTO Cases



In the era when the Japanese market depended on imports for PCI GW, Japanese KOL requested major manufacturers to make a wire for CTO PCI but were turned down.

※KOL(Key Opinion Leader)

··· A physician with influence over the direction of PCI.


PCI GW for CTO Procedures (1995)

Aggressive expansion of CTO cases via minimally invasive procedures




Our Strength:

Competitive Power in Medical Devices" Based on "High Technology for Raw Material



Our Strength: Merits of Segmental Structure (fusion/combination/circulation)



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

[IR contact]

Asahi Intecc Co., Ltd. corporate strategic office

TEL 0561-56-1851 URL https://www.asahi-intecc.co.jp/en

